Figure 4. NK cells in peripheral blood cells of renal transplant patients.

(A) Total lymphocyte counts, (B) CD3⁺ lymphocyte counts, (C) NK cell counts and (D) CD3⁻, CD16⁺, CD56^dim : CD56^bright NK cell ratios in healthy controls, early transplant patients having received either alemtuzumab or basiliximab, and late transplant patients. The data demonstrate that alemtuzumab treatment is associated with reduced total lymphocyte counts, CD3⁺ lymphocyte counts and NK cell counts. Values are individual patients and bars represent means. (* p<0.05 with ANOVA followed by Dunnett's test or Tukey's test).